NHC’s 2019 tasks include managing new EDL, RDL drug listings



The National Health Commission (NHC) standing committee held its first press conference of the new year, when progress during 2018 and medical work priorities for the new year were up for discussion.

A total of 10 ten key work tasks for 2019 were outlined by NHC deputy spokesperson Hu Qiangqiang. Of most significance for the pharmaceutical market will be the ongoing efforts to promote “Unified medicine”, referring to reforms to link drug policy, the Essential Drug List (EDL) system, and Basic Medical Insurance (BMI) payment reforms.

Among the key focus points for the NHC will be implementation and management of last year’s new EDL and Reimbursement Drug List (RDL) listings. The NHC added 12 cancer and hepatitis C virus drugs to the EDL, while the State Medical Insurance Administration (SMIA) added 17 oncology drugs to the RDL after price negotiations. The NHC will therefore be strongly focused on devising clinical pathways and drug guidelines to guide usage of the new listings. The NHC spokesperson confirmed that the 17 new RDL listings for cancer drugs will not be included in general hospital reform targets to reduce the amount of hospital income derived from drug sales. However, guidelines on what constitutes fair usage of these drugs will also need to be devised.

The NHC also revealed that last year’s 17 new anti-cancer RDL listings have now been made available in 1,386 hospitals across China’s 32 provinces and regions, with a over 600,000 product units administered to patients.
Reference:

Related news
A group of Chinese R&D-based biotechs have in recent weeks gained central government support under the Major National Science and Technology Project for New Drug Research and Development program. According to company announcements, awards have been given to: - Antengene to reflect its development of ATG-008, a category 1 dual TOC1/2 inhibitor currently under Phase II/III study for advanced hepatocellular carcinoma (HCC); - BeiGene for PARP inhibitor BGB-290; - Acea Pharma for the third-generation EGFR inhibitor avitinib; - Zai Lab for development of the PARP inhibitor ZL-2306 (niraparib); - I-Mab for interleukin-6 (IL-6) trans-signaling blocker TJ301’s development in urothelial carcinoma; -&
China’s National Health Commission (NHC) pledged to release lists of generic drugs that should be prioritized for development by drug manufacturers starting in June this year, according to a Notice.
China’s National Health Commission (NHC) released a notice setting out diagnosis and treatment norms for hospitals in relation to 18 different cancer indications.
During a session of the National People’s Congress Standing Committee, officials outlined China’s spending on health in recent years.
A total of 13 provinces have begun to implement local Essential Drug Lists (EDLs) following the release of the national list in October by the National Health Commission (NHC).
Recent news
A group of scientists at the National Autonomous University of Mexico (UNAM) are developing a combination therapy of six off-patent cancer drugs, half of which inhibit tumor growth while the other three prevent weight loss resulting from catabolism.
Notimex ・Hace 41 mins Científicos de la UNAM trabajan para encontrar fármacos de bajo costo contra el cáncer Científicos de la Universidad Nacional Autónoma de México (UNAM) trabajan en la línea de investigación denominada “reposicionamiento terapéutico” / Foto: Twitter @unamglobal Las compañías farmacéuticas dedicadas a combatir el cáncer sintetizan las moléculas que combaten la enfermedad, las optimizan, las prueban en el laboratorio y finalmente en los pacientes. Científicos de la Universidad Nacional Autónoma de México (UNAM) trabajan en la línea de investigación denominada “reposicionamiento terapéutico”, que consiste en estudiar medicamentos comercializados que perdieron la patente y que tienen efectos antitumorales. En específico analizan seis sustancias, tres de las cuales inhiben el crecimiento del tumor y tres más que evitan el catabolismo del paciente, manifestado como pérdida peso.
Brazil’s National Health Surveillance Agency (ANVISA) has granted registration to generic antibiotic levofloxacin hemihydrate, manufactured by global pharmaceutical company Eurofarma Laboratórios S.A. The registration is for two 150ml presentations, and will expire after 24 months.
Por: Ascom/Anvisa Publicado: 09/01/2019 11:17 Última Modificação: 09/01/2019 19:57 A Agência Nacional de Vigilância Sanitária (Anvisa) liberou o registro de um novo medicamento genérico. É o levofloxacino hemi-hidratado, na forma farmacêutica solução injetável para infusão.
Jhenery Ramírez jhenery.ramirez@listindiario.com Santo Domingo En el año 2018 el Programa de Medicamentos Esenciales Central de Apoyo Logístico (Promese/Cal) despachó medicinas por un valor de RD$979.9 millones, razón por la que el país (tanto la población como el Gobierno) ahorró RD$7,550.6 millones en comparación a la compra al sector privado. Las cifras, presentadas ayer por el director general de la entidad, Antonio Peña Mirabal, corresponden a medicamentos dispensados por las Farmacias del Pueblo y los hospitales que son subsidiados por el Gobierno dominicano. El informe “Impacto Financiero 2018” de Promese destaca que mientras el sector privado despachó estimadamente RD$3,332.5 millones en medicinas, la institución expidió RD$738.7 millones en medicamentos en los hospitales, ahorrando al Estado RD$2,593.7 millones. Además, la información suministrada durante un encuentro de la organización con la prensa económica indica que el monto despachado por las Farmacias del Pueblo fue de RD$241.1 millones, en comparación al monto estimado de venta del sector privado de RD$5,198 millones, lo que permitió un ahorro a la población de RD$4,956.9 millones. Presupuesto Peña Mirabal expresó que la asignación presupuestaria recibida en el año 2018 fue de RD$3,635.3 millones, de los cuales RD$2,730 millones estaban destinados a materiales y suministros; RD$588.2 millones fueron para las remuneraciones y contribuciones.
The entry of China-made programmed death-1 (PD-1) inhibitors is set to provide a significant challenge to MNC competitors.
  • 1547538873583
  • China
According to a financial report presented by Antonio Peña Mirabal, head of the Dominican Republic’s Essential Drugs Programme and Logistical Support (PROMESE/CAL), the state supplied a total DOP 980 million (USD 19 million) worth of subsidized medicines to hospitals and its People’s Pharmacy Network.
Analytics Snapshot


Understand the facts and anticipate market shifts. Get the facts here.